CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) announced a 1-for-10 reverse stock split effective June 1, 2022, at 5:00 p.m. ET. This decision, approved by stockholders at the Annual Meeting on May 25, aims to meet NASDAQ's minimum bid price requirement. Following the split, approximately 13,606,249 shares will remain outstanding. The reverse split is expected to enhance the company's ability to access capital markets and support future growth in hematology and oncology therapeutics. CASI will trade post-split under the same NASDAQ symbol beginning June 2, 2022.
- Reverse stock split improves compliance with NASDAQ listing rules.
- Stockholders approved the split, indicating support for the company's strategy.
- Enhanced ability to access capital markets post-split.
- None.
ROCKVILLE, Md. and BEIJING, May 26, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-10 reverse stock split that will become effective at 5:00 p.m., Eastern Time, on June 1, 2022. The primary objective of implementing a reverse split is to satisfy the minimum bid price requirement for continued listing on The NASDAQ Capital Market (Rule 5550(a)(1)).
At CASI's Annual Meeting of Stockholders held on May 25, 2022, stockholders voted to approve a proposal authorizing the Board of Directors, at its discretion, to implement a reverse split at a ratio between 1-for-2 and 1-for-20 of the Company's common stock without further action from stockholders, and, as authorized, the Board of Directors has elected to implement a reverse split at the ratio of 1-for-10.
Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We appreciate the continued support of our stockholders in granting our Board of Directors the authority to implement a reverse split. After in-depth consideration of our options, the Board determined that a reverse split of the Company's stock is in the best interest of stockholders."
Dr. He continued, "By implementing a reverse stock split, the Company is better positioned to regain compliance with the NASDAQ listing rules. Maintaining our listing on NASDAQ will provide the Company with greater flexibility with respect to access to the capital markets. In 2022 CASI will continue to advance the development and commercialization of our portfolio with a focus on creating shareholders' value."
Details of the Reverse Split
At the effective time of the reverse stock split at 5:00 p.m., Eastern Time, on June 1, 2022, every 10 shares of CASI's pre-split common stock, par value,
Additional information, can be accessed directly at www.casipharmaceuticals.com and in the Company's definitive proxy statement filed with the SEC on April 15, 2022.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, revenue growth, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors.
COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 | INVESTOR CONTACT: Xuan Yang Solebury Trout 646.378.2975 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-reverse-stock-split-301556083.html
SOURCE CASI Pharmaceuticals, Inc.
FAQ
What is the date of CASI's reverse stock split?
What is the reverse stock split ratio for CASI?
Why did CASI Pharmaceuticals decide to conduct a reverse stock split?
How many shares will CASI have after the reverse stock split?
Will the reverse stock split affect my ownership percentage in CASI?
